Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies

Authors: Hui Yang, Stefan Kurtenbach, Ying Guo, Ines Lohse, Michael Durante, Jianping Li, Zhaomin Li, Hassan Al‐Ali, Lingxiao Li, Zizhen Chen, Matthew G. Field, Peng Zhang, Shi Chen, Shohei Yamamoto, Zhuo Li, Yuan Zhou, Stephen D. Nimer, J. William Harbour, Claes Wahlestedt, Mingjiang Xu, Feng‐Chun Yang - Blood 2017 cited by 167

Key Points Transgenic expression of ASXL1aa1-587 truncating protein in the hematopoietic system leads to diverse myeloid malignancies in mice. ASXL1aa1-587 gains an interaction with BRD4 and Asxl1Y588XTg hematopoietic stem/progenitor cells are hypersensitive to BET bromodomain inhibitors.